Cognitive Remediation Therapy in Anorexia Nervosa
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jan 17, 2013
Trial Information
Current as of July 03, 2025
Completed
Keywords
ClinConnect Summary
"Several studies have documented that patients with Anorexia Nervosa (AN) display a trait of cognitive inflexibility (e;g., poor set-shifting performances on the Trail Making Task B), i.e. an inability to move flexibly back and forth between tasks, operations, or mental sets which allows for the adaptation of behaviour in response to changing demands within the environment. This cognitive inflexibility can be observed both during the acute phase of the illness and after weight restoration, and has been found to predict negative treatment outcomes. 'Weak central coherence' is another skill w...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • female;
- • 15-40 years old;
- • hospitalised for a diagnosis of Anorexia Nervosa (DSM-IV Revised criteria) in one of the three departments participating in this research ;
- • fluent in French;
- • who provide their informed consent (or as far as possible their parents for those under 18).
- Exclusion Criteria:
- • previous history of neurological disorders;
- • actual substance use disorder;
- • schizophrenia;
- • presenting a related somatic illness (diabetes, Crohn's disease, metabolic illness) or a life-threatening condition.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Paris, , France
Paris, , France
Villejuif, , France
Patients applied
Trial Officials
Sylvie BERTHOZ, PhD
Study Director
Institut National de la Santé Et de la Recherche Médicale, France
Damien RINGUENET, MD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials